Short term Efficacy and Safety of Alpha Interferon -2b (Pasture Made) plus Ribavirin for Treatment of the Patients with Chronic Hepatitis C

Pasteur Institute of Iran (IPI)0 个研究点目标入组 100 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Inclusion Criteria: Impossibility for administration of peg-interferon according to recommendation of relevant specialist, older than 18 years, HCV RNA in serum on polymerase-chain-reaction (PCR) assay

•decompensated cirrhosis, autoimmune disease, evidence of cancer on ultrasonography or a high serum alfa-fetoprotein concentration, co-infection with HBV or HIV, neutropenia (neutrophil count <1500 cells/mm3), thrombocytopenia (platelet count <90,000 cells/mm3), anemia (hemoglobin level <12 gr/dl for women and <13 gr/dl for men), creatinine concentration more than 1.5 times the upper limit of normal range, organ transplantation, neoplastic disease, severe cardiac or chronic pulmonary disease, poorly controlled psychiatric disorder, seizure disorder, retinopathy, active drug or alcohol abuse, pregnancy in patient or spouse or unwillingness to use contraception.

发起方

Pasteur Institute of Iran (IPI)